Acurx Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

12 Months Ended

Dec. 31, 2021

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of December 31, 2021 and 2020 were as follows:


	December 31, 2021		December 31, 2020
Accrued compensation expenses	$	508,343	$	317,068
Accrued research and development		229,090		89,156
Accrued professional fees		43,102		49,707
Other accounts payable and accrued expenses		63,374		—
Total	$	843,909	$	455,931